J. B. Chemicals & Pharmaceuticals Limited
JBCHEPHARM
Peringkat dalam Saham
#3899
J. B. Chemicals & Pharmaceuticals Limited, an enterprise founded in Mumbai,... J. B. Chemicals & Pharmaceuticals Limited, an enterprise founded in Mumbai, India, in 1976, specializes in the development, production, and global distribution of diverse pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients. Among its prominent product offerings are Cilnidipine, Ranitidine, and Metronidazole. Beyond its own brands, the company extends comprehensive contract manufacturing services, covering an extensive spectrum of dosage forms such as tablets, various lozenge types, injectables, gels, creams, ointments, liquid herbal syrups, and capsules. The firm further contributes to diagnostic medicine by supplying contrast agents for advanced imaging techniques like X-ray, MRI, and ultrasound. Its therapeutic expertise encompasses a broad range of medical fields, including gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives, and pharmacovigilance.
Harga Saham
$26.58
Terakhir disinkronkan: 2026-07-23
Kapitalisasi Pasar
$4.24B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
38.40%
Negara
IN
Perdagangan J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM)
Kategori
Healthcare
Pendapatan untuk J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM)
Pendapatan pada Mar 2026 TTM: $457.75M
Menurut laporan keuangan terbaru dari J. B. Chemicals & Pharmaceuticals Limited, pendapatan saat ini (TTM) adalah $457.75M. Pada tahun 2024, perusahaan menghasilkan pendapatan sebesar $417.85M peningkatan dibandingkan pendapatan pada tahun 2023 yang sebesar $379.23M. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan J. B. Chemicals & Pharmaceuticals Limited dari 2005 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Mengubah |
|---|---|---|
| 2026 (TTM) | $457.75M | -0.08% |
| 2025 | $458.10M | 9.63% |
| 2024 | $417.85M | 10.19% |
| 2023 | $379.23M | 18.75% |
| 2022 | $319.36M | 16.55% |
| 2021 | $274.01M | 18.45% |
| 2020 | $231.33M | -0.24% |
| 2019 | $231.89M | 9.00% |
| 2018 | $212.73M | 5.28% |
| 2017 | $202.07M | 14.60% |
| 2016 | $176.33M | 4.91% |
| 2015 | $168.07M | 7.33% |
| 2014 | $156.59M | 8.27% |
| 2013 | $144.63M | -8.54% |
| 2012 | $158.14M | -16.27% |
| 2011 | $188.85M | 14.47% |
| 2010 | $164.98M | 16.80% |
| 2009 | $141.25M | 0.50% |
| 2008 | $140.54M | 15.92% |
| 2007 | $121.24M | 15.95% |
| 2006 | $104.56M | 27.21% |
| 2005 | $82.19M | 0.00% |
Pendapatan untuk perusahaan serupa atau pesaing
| Perusahaan | Pendapatan | Perbedaan Pendapatan | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 1,344.40% |
IN
|
